TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be co...
Main Authors: | Joseph G. Skeate, Mikk E. Otsmaa, Ruben Prins, Daniel J. Fernandez, Diane M. Da Silva, W. Martin Kast |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00922/full |
Similar Items
-
TNFSF4 Gene Variations Are Related to Early-Onset Autoimmune Thyroid Diseases and Hypothyroidism of Hashimoto’s Thyroiditis
by: Rong-Hua Song, et al.
Published: (2016-08-01) -
Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population
by: Zuqiang Fu, et al.
Published: (2021-03-01) -
Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level via 998 Samples With Brain Glioma
by: Ying Yang, et al.
Published: (2021-08-01) -
Clinical Significance and Advances of TNFSF15 Modulation on Tumor Angiogenesis and Lymphangiogenesis
by: QIN Tingting, et al.
Published: (2020-07-01) -
LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
by: Giacomina Brunetti, et al.
Published: (2018-10-01)